^
RET mutation
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: A1 - Approval
NICE - 2 weeks
RET fusion
Thyroid Gland Carcinoma
selpercatinib
Sensitive: A1 - Approval
NICE - 2 weeks
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A1 - Approval
RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Carcinoma
cabozantinib tablet
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
sorafenib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Follicular Carcinoma
sorafenib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Papillary Carcinoma
sorafenib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Follicular Carcinoma
lenvatinib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
lenvatinib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Medullary Carcinoma
vandetanib
Sensitive: A1 - Approval
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive: A1 - Approval
RET mutation
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: A1 - Approval
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
dabrafenib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Carcinoma
lenvatinib
Sensitive: A1 - Approval
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Medullary Carcinoma
dacarbazine
Sensitive: A2 - Guideline
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Anaplastic Carcinoma
CaT
Sensitive: A2 - Guideline
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: A2 - Guideline
TMB-H
Thyroid Gland Hurthle Cell Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
denosumab
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Follicular Carcinoma
denosumab
Sensitive: A2 - Guideline
TMB-H
Thyroid Gland Follicular Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
selpercatinib
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Follicular Carcinoma
selpercatinib
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Papillary Carcinoma
denosumab
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Medullary Carcinoma
denosumab
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Anaplastic Carcinoma
cisplatin
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Anaplastic Carcinoma
docetaxel + doxorubicin hydrochloride
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Anaplastic Carcinoma
doxorubicin hydrochloride
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Anaplastic Carcinoma
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib tablet
Sensitive: A2 - Guideline
TMB-H
Thyroid Gland Medullary Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Papillary Carcinoma
selpercatinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Papillary Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Thyroid Gland Papillary Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Anaplastic Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Thyroid Gland Anaplastic Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Thyroid Gland Anaplastic Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive: A2 - Guideline
TMB-H
Thyroid Gland Papillary Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
RET mutation
Thyroid Gland Anaplastic Carcinoma
selpercatinib
Sensitive: A2 - Guideline
RET M918T
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
KRAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
NRAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
HRAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Papillary Carcinoma
pralsetinib
Sensitive: A2 - Guideline
TMB-H
Thyroid Gland Anaplastic Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
pralsetinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Hurthle Cell Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
larotrectinib
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Follicular Carcinoma
pralsetinib
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Anaplastic Carcinoma
carboplatin + paclitaxel
Sensitive: A2 - Guideline
RET fusion
Thyroid Gland Anaplastic Carcinoma
pralsetinib
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Carcinoma
AIC100
Sensitive: B - Late Trials
No biomarker
Thyroid Gland Anaplastic Carcinoma
AIC100
Sensitive: B - Late Trials
BRAF V600
Thyroid Gland Carcinoma
vemurafenib
Sensitive: C1 - Off-label
NTRK3 fusion
Thyroid Gland Carcinoma
larotrectinib
Sensitive: C1 - Off-label
NTRK1 fusion
Thyroid Gland Carcinoma
larotrectinib
Sensitive: C1 - Off-label
NTRK2 fusion
Thyroid Gland Carcinoma
larotrectinib
Sensitive: C1 - Off-label
BRAF V600E
Thyroid Gland Carcinoma
dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
Thyroid Gland Carcinoma
trametinib
Sensitive: C1 - Off-label
BRAF V600E
Thyroid Gland Papillary Carcinoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
EGFR L858R
Thyroid Gland Anaplastic Carcinoma
erlotinib
Sensitive: C1 - Off-label
BRAF V600E
Thyroid Gland Papillary Carcinoma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
vemurafenib
Resistant: C1 - Off-label
BRAF V600E
Thyroid Gland Carcinoma
vemurafenib
Sensitive: C1 - Off-label
PD-L1 expression
Thyroid Gland Carcinoma
pembrolizumab
Sensitive: C1 - Off-label
BRAF mutation
Thyroid Gland Carcinoma
selumetinib
Sensitive: C2 – Inclusion Criteria
NRAS mutation
Thyroid Gland Carcinoma
selumetinib
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Thyroid Gland Papillary Carcinoma
trametinib + dabrafenib
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive: C2 – Inclusion Criteria
RET mutation
Thyroid Gland Medullary Carcinoma
TPX 0046
Sensitive: C2 – Inclusion Criteria
RET mutation
Thyroid Gland Medullary Carcinoma
BOS-172738
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Thyroid Gland Papillary Carcinoma
vemurafenib
Sensitive: C2 – Inclusion Criteria
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive: C2 – Inclusion Criteria
HRAS mutation
Thyroid Gland Carcinoma
trametinib
Sensitive: C2 – Inclusion Criteria
KRAS mutation
Thyroid Gland Carcinoma
trametinib
Sensitive: C2 – Inclusion Criteria
NRAS mutation
Thyroid Gland Carcinoma
trametinib
Sensitive: C2 – Inclusion Criteria